A Study of Baricitinib (LY3009104) in Children With COVID-19
Terminated · Phase 3 · NCT05074420
Conditions: Covid19, Corona Virus Infection
At a glance
- Research payments reported, 2025
- $3,575
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 6
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Baricitinib (drug)
- Dates
- Started 2021-12-21; completion 2024-11-04
- Results posted
- Yes
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
From ClinicalTrials.gov, last updated 2026-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3,575 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Federico R. Laham, M.D. Pediatric Infectious Disease · Orlando, FL
- Ankita P. Desai, MD Pediatric Infectious Disease · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.